Altimmune to Participate at Two Upcoming Investor Conferences
30 Août 2023 - 1:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that members of the Company’s management
team will participate and be available for 1x1 meetings at the
following investor conferences:
- Wells Fargo 2023 Healthcare Conference in Everett,
MAWednesday, September 6, 2023Fireside chat at 3:45 pm
Eastern Time
- Morgan Stanley 21st Annual Global Healthcare Conference
in New York, NYWednesday, September 13, 2023Fireside chat
at 1:35 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the
Events section of the Altimmune website.
About AltimmuneAltimmune is a clinical-stage
biopharmaceutical company focused on developing innovative
next-generation therapeutics for the treatment of obesity and liver
diseases. The Company’s lead product candidate, pemvidutide, is a
GLP-1/glucagon dual receptor agonist that is being developed for
the treatment of obesity and NASH. In addition, Altimmune is
developing HepTcell™, an immunotherapeutic designed to achieve a
functional cure for chronic hepatitis B. For more information,
please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Altimmune Investor & Media Contact:
Richard EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Altimmune (NASDAQ:ALT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Altimmune (NASDAQ:ALT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024